Previous studies demonstrated that IL‐18 could be a candidate for targeting therapy of human cancers since it possesses an antitumor effect due to recognition of NK cell receptors 33 or activates the p38 mitogen‐activated protein kinase signaling pathway 35, 36. This evidence concerns the gene KLRD1 and cancer.